Compare Automatic Data Processing Inc (ADP) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Amphastar Pharmaceuticals Inc — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $108.72B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Automatic Data Processing Inc is far larger — about 125.8× Amphastar Pharmaceuticals Inc's market cap, and Automatic Data Processing Inc pays a 2.48% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ADP | AMPH | |
|---|---|---|
Market Cap | $108.72B | $863.95M |
Sector | Industrials | Health |
52-Week High | $309.03 | $30.81 |
52-Week Low | $188.79 | $16.87 |
Enterprise Value | $109.76B | $1.26B |
Dividend Yield | 2.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $271.32, down 0.8% for the day, with strong technical momentum showing bullish moving averages and key support at $269. The company demonstrates robust fundamentals with consistent earnings beats, 20.11% net margins, and 72.24% ROE. Recent Q4 2026 results showed 7% revenue growth and 17% EPS growth, driving positive analyst sentiment despite elevated valuation multiples.
Outlook remains positive with a $280.50 consensus price target offering 3.4% upside potential. Key opportunities include margin expansion and dividend stability, while risks center on high valuation sensitivity and labor market volatility affecting ADP's payroll processing business. The stock presents a quality growth opportunity with disciplined risk management required.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
